×
About 13,394 results

ALLMedicine™ Myelodysplastic Syndromes Center

Research & Reviews  6,373 results

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based...
https://doi.org/10.1200/JCO.20.03380
Journal of Clinical Oncology : Official Journal of the Am... Nakamura R, Saber W et. al.

Jun 9th, 2021 - Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to older patients. The relative benefits of HCT over non-HCT therapy in older pat...

Targeting health-related quality of life in patients with myelodysplastic syndromes - C...
https://doi.org/10.1016/j.blre.2021.100851
Blood Reviews; Oliva EN, Platzbecker U et. al.

Jun 5th, 2021 - Using a range of health-related quality of life (HRQoL) instruments, most - but not all - studies of myelodysplastic syndromes (MDS) have reported that lower hemoglobin levels and red blood cell transfusion dependency are associated with worse HRQ...

Regulation of RNA Polymerase II Activity is Essential for Terminal Erythroid Maturation.
https://doi.org/10.1182/blood.2020009903
Blood Murphy Z, Murphy K et. al.

Jun 2nd, 2021 - The terminal maturation of human erythroblasts requires significant changes in gene expression in the context of dramatic nuclear condensation. Defects in this process are associated with inherited anemias and myelodysplastic syndromes. The progre...

Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MD...
https://doi.org/10.1111/bjh.17537
British Journal of Haematology; Amitai I, Geddes M et. al.

Jun 1st, 2021 - The incorporation of patient-reported outcomes with traditional disease risk classification was found to strengthen survival prediction in patients with myelodysplastic syndromes (MDS). In the present Canadian MDS registry analysis, we validate a ...

Iron Overload-Induced Oxidative Stress in Myelodysplastic Syndromes and its Cellular Se...
https://doi.org/10.1016/j.critrevonc.2021.103367
Critical Reviews in Oncology/hematology; Kim CH, Leitch HA

May 31st, 2021 - The myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders. MDS patients often require red blood cell transfusions, resulting in iron overload (IOL). IOL increases production of reactive oxygen species (ROS), oxygen free radi...

see more →

Guidelines  31 results

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment a...
https://doi.org/10.1016/j.annonc.2020.11.002
Annals of Oncology : Official Journal of the European Soc... Fenaux P, Haase D et. al.

Nov 22nd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|

Considerable Variation Exists in Receipt of Complete Diagnostic Evaluations for Myelodysplastic Syndromes Among Medicare Patients
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/

May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).

Hematology Quality Metrics
http://www.hematology.org/Clinicians/Guidelines-Quality/503.aspx
Allen, S.

Feb 20th, 2018 - These clinical performance measures are designed for individual quality improvement. Some of the measures may also be appropriate for accountability if appropriate sample sizes and implementation rules are achieved.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0007
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Stone RM et. al.

Jan 3rd, 2017 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the p...

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from...
http://www.bloodjournal.org/content/122/17/2943
Malcovati, L.,et al.

Oct 23rd, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit.

see more →

Drugs  59 results see all →

Clinicaltrials.gov  6,633 results

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based...
https://doi.org/10.1200/JCO.20.03380
Journal of Clinical Oncology : Official Journal of the Am... Nakamura R, Saber W et. al.

Jun 9th, 2021 - Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to older patients. The relative benefits of HCT over non-HCT therapy in older pat...

Targeting health-related quality of life in patients with myelodysplastic syndromes - C...
https://doi.org/10.1016/j.blre.2021.100851
Blood Reviews; Oliva EN, Platzbecker U et. al.

Jun 5th, 2021 - Using a range of health-related quality of life (HRQoL) instruments, most - but not all - studies of myelodysplastic syndromes (MDS) have reported that lower hemoglobin levels and red blood cell transfusion dependency are associated with worse HRQ...

Regulation of RNA Polymerase II Activity is Essential for Terminal Erythroid Maturation.
https://doi.org/10.1182/blood.2020009903
Blood Murphy Z, Murphy K et. al.

Jun 2nd, 2021 - The terminal maturation of human erythroblasts requires significant changes in gene expression in the context of dramatic nuclear condensation. Defects in this process are associated with inherited anemias and myelodysplastic syndromes. The progre...

Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MD...
https://doi.org/10.1111/bjh.17537
British Journal of Haematology; Amitai I, Geddes M et. al.

Jun 1st, 2021 - The incorporation of patient-reported outcomes with traditional disease risk classification was found to strengthen survival prediction in patients with myelodysplastic syndromes (MDS). In the present Canadian MDS registry analysis, we validate a ...

Iron Overload-Induced Oxidative Stress in Myelodysplastic Syndromes and its Cellular Se...
https://doi.org/10.1016/j.critrevonc.2021.103367
Critical Reviews in Oncology/hematology; Kim CH, Leitch HA

May 31st, 2021 - The myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders. MDS patients often require red blood cell transfusions, resulting in iron overload (IOL). IOL increases production of reactive oxygen species (ROS), oxygen free radi...

see more →

News  289 results

Whole-Genome Sequencing Emerging for Routine Cancer Care
https://www.medscape.com/viewarticle/947261

Mar 10th, 2021 - Almost 20 years after the human genome was first mapped, whole-genome sequencing might finally be ready to enter routine cancer care. Researchers at Washington University in St. Louis, St. Louis, Missouri, are commercializing an automated sequenci...

Myelodysplastic Syndromes Clinical Practice Guidelines (ESMO, 2021)
https://reference.medscape.com/viewarticle/944879

Feb 2nd, 2021 - Guidelines on the diagnosis and treatment of myelodysplastic syndromes were published in November 2020 by the European Society of Medical Oncology.[1] The diagnosis of myelodysplastic syndromes (MDS) is based on the blood count, the marrow aspirat...

FDA Approves Oral Therapy for Myelodysplastic Syndromes, CMML
https://www.medscape.com/viewarticle/933602

Jul 7th, 2020 - The Food and Drug Administration has approved Inqovi (decitabine and cedazuridine tablets, Astex Pharmaceuticals) to treat adults with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The agency's action gives physicians ...

Considerable Variation Exists in Receipt of Complete Diagnostic Evaluations for Myelodysplastic Syndromes Among Medicare Patients
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/

May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).

First Advance in MDS for Decade: Luspatercept for Anemia
https://www.medscape.com/viewarticle/928198

Apr 5th, 2020 - The US Food and Drug Administration (FDA) has approved luspatercept (Reblozyl, Bristol-Myers Squibb/Acceleron) for the treatment of anemia in patients with myelodysplastic syndromes (MDS). The green light represents the first treatment advancement...

see more →

Patient Education  9 results see all →